ROBERT ALSPACH

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD

Sickle cell disease focused legislation, federal funding, and federal programs.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for an RNA platform approach to medicine, including protein replacements, gene editing and cell engineering strategies, immunotherapies and vaccines to treat cancer, rare disease, autoimmunity and other chronic and infectious illnesses for the benefit of patients, public health, and society.

Pharmaceutical, medical products, and patient safety issues.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD

Sickle cell disease focused legislation, federal funding, and federal programs.

Pharmaceutical and patient safety issues.

Clinical research, data privacy, artificial intelligence.

Pharmaceutical and patient safety issues.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.

Sickle cell disease focused legislation, federal funding, and federal programs.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Sickle cell disease focused legislation, federal funding, and federal programs.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.

Pharmaceutical and patient safety issues.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.

Sickle cell disease focused legislation, federal funding, and federal programs.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Pharmaceutical and patient safety issues.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Pharmaceutical and patient safety issues.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Pharmaceutical and patient safety issues.

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Improvements to the 340B drug discount program.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Pharmaceutical and patient safety issues.

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Improvements to the 340B drug discount program.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Pharmaceutical and patient safety issues.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Improvements to the 340B drug discount program.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Pharmaceutical and patient safety issues.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Improvements to the 340B drug discount program.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Pharmaceutical and patient safety issues.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Improvements to the 340B drug discount program.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Pharmaceutical and patient safety issues.

Improvements to the 340B drug discount program.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

-330 Funding -Health Care Workforce Issues -Program for All-Inclusive Care for the Elderly

Pharmaceutical and patient safety issues.

Improvements to the 340B drug discount program.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Pharmaceutical and patient safety issues.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Strengthening America's Families Act (HR 2973)to establish infant-toddler court programs to better address the needs of families with infants and toddlers in the child welfare system.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.

Pharmaceutical and patient safety issues.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.

Pharmaceutical and patient safety issues.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Strengthening America's Families Act (HR 2973)to establish infant-toddler court programs to better address the needs of families with infants and toddlers in the child welfare system.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Pharmaceutical and patient safety issues.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Pharmaceutical and patient safety issues.

Strengthening America's Families Act (HR 2973)to establish infant-toddler court programs to better address the needs of families with infants and toddlers in the child welfare system.

​Pharmaceutical and patient safety issues.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Strengthening America's Families Act (HR 2973)to establish infant-toddler court programs to better address the needs of families with infants and toddlers in the child welfare system.

​Pharmaceutical and patient safety issues.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Strengthening America's Families Act (HR 2973)to establish infant-toddler court programs to better address the needs of families with infants and toddlers in the child welfare system.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.

330 Funding, Health Care Workforce Issues, Program for All-Inclusive Care for the Elderly.

Issues related to the creation of a Neuroscience Center of Excellence at FDA.